MX2020008533A - Terapia con oligonucleotidos para la enfermedad de wilson. - Google Patents

Terapia con oligonucleotidos para la enfermedad de wilson.

Info

Publication number
MX2020008533A
MX2020008533A MX2020008533A MX2020008533A MX2020008533A MX 2020008533 A MX2020008533 A MX 2020008533A MX 2020008533 A MX2020008533 A MX 2020008533A MX 2020008533 A MX2020008533 A MX 2020008533A MX 2020008533 A MX2020008533 A MX 2020008533A
Authority
MX
Mexico
Prior art keywords
exon
atp7b
flanking
wilson disease
flanking intron
Prior art date
Application number
MX2020008533A
Other languages
English (en)
Spanish (es)
Inventor
Frank Schmitges
Daniele Merico
Erno Wienholds
Matthew O''HARA
Original Assignee
Deep Genomics Incorporated
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Deep Genomics Incorporated filed Critical Deep Genomics Incorporated
Publication of MX2020008533A publication Critical patent/MX2020008533A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C12N15/1137—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/11—Antisense
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/31—Chemical structure of the backbone
    • C12N2310/315—Phosphorothioates
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/33—Chemical structure of the base
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/35—Nature of the modification
    • C12N2310/352—Nature of the modification linked to the nucleic acid via a carbon atom
    • C12N2310/3525—MOE, methoxyethoxy
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2320/00—Applications; Uses
    • C12N2320/30—Special therapeutic applications
    • C12N2320/33—Alteration of splicing
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y306/00—Hydrolases acting on acid anhydrides (3.6)
    • C12Y306/03—Hydrolases acting on acid anhydrides (3.6) acting on acid anhydrides; catalysing transmembrane movement of substances (3.6.3)
    • C12Y306/03004—Cu2+-exporting ATPase (3.6.3.4)

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Biomedical Technology (AREA)
  • Chemical & Material Sciences (AREA)
  • Molecular Biology (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biophysics (AREA)
  • Microbiology (AREA)
  • Plant Pathology (AREA)
  • Biochemistry (AREA)
  • Physics & Mathematics (AREA)
  • Virology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
MX2020008533A 2018-02-14 2019-02-14 Terapia con oligonucleotidos para la enfermedad de wilson. MX2020008533A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201862630565P 2018-02-14 2018-02-14
PCT/US2019/018076 WO2019161105A1 (en) 2018-02-14 2019-02-14 Oligonucleotide therapy for wilson disease

Publications (1)

Publication Number Publication Date
MX2020008533A true MX2020008533A (es) 2020-11-06

Family

ID=67619598

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2020008533A MX2020008533A (es) 2018-02-14 2019-02-14 Terapia con oligonucleotidos para la enfermedad de wilson.

Country Status (15)

Country Link
US (1) US11578327B2 (cg-RX-API-DMAC7.html)
EP (1) EP3752614A4 (cg-RX-API-DMAC7.html)
JP (1) JP2021513851A (cg-RX-API-DMAC7.html)
KR (1) KR20200120675A (cg-RX-API-DMAC7.html)
CN (1) CN112041439A (cg-RX-API-DMAC7.html)
AU (1) AU2019222767A1 (cg-RX-API-DMAC7.html)
BR (1) BR112020016524A2 (cg-RX-API-DMAC7.html)
CA (1) CA3090517A1 (cg-RX-API-DMAC7.html)
CL (1) CL2020002100A1 (cg-RX-API-DMAC7.html)
CO (1) CO2020010226A2 (cg-RX-API-DMAC7.html)
IL (1) IL276701A (cg-RX-API-DMAC7.html)
MX (1) MX2020008533A (cg-RX-API-DMAC7.html)
PH (1) PH12020551219A1 (cg-RX-API-DMAC7.html)
SG (1) SG11202007644PA (cg-RX-API-DMAC7.html)
WO (1) WO2019161105A1 (cg-RX-API-DMAC7.html)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2025110984A1 (en) * 2023-11-21 2025-05-30 Hydrogene Therapeutics, Inc. Compositions and methods for treating wilson's disease
CN117925624B (zh) * 2024-03-22 2024-05-31 上海凌医生物科技有限公司 一种金属响应调控元件

Family Cites Families (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3687808A (en) 1969-08-14 1972-08-29 Univ Leland Stanford Junior Synthetic polynucleotides
US5578493A (en) * 1993-09-01 1996-11-26 The Trustees Of Columbia University In The City Of New York Wilson's disease gene
CA2108927C (en) 1993-09-21 2008-09-02 Peter Bull Wilson disease gene
TW520293B (en) 1995-11-22 2003-02-11 Univ Johns Hopkins Med Delivery system to enhance cellular uptake of biomolecules
US20040101854A1 (en) * 2002-11-21 2004-05-27 Isis Pharmaceuticals Inc. Modulation of BCL2-associated athanogene expression
US7491805B2 (en) 2001-05-18 2009-02-17 Sirna Therapeutics, Inc. Conjugates and compositions for cellular delivery
US20030180953A1 (en) 2000-12-29 2003-09-25 Elitra Pharmaceuticals, Inc. Gene disruption methodologies for drug target discovery
US20040126761A1 (en) * 2002-12-10 2004-07-01 Isis Pharmaceuticals Inc. Modulation of alpha-methylacyl-CoA racemase expression
WO2004035819A2 (en) 2002-10-21 2004-04-29 Exiqon A/S Oligonucleotide analogues for detecting and analyzing nucleic acids
US20050244851A1 (en) 2004-01-13 2005-11-03 Affymetrix, Inc. Methods of analysis of alternative splicing in human
EP1718741A2 (en) * 2004-01-29 2006-11-08 Cellzome Ag Treatment of neurodegenerative diseases by the use of atp7a
CA2566286A1 (en) 2004-05-11 2005-12-08 Rnai Co., Ltd. Polynucleotide causing rna interfere and method of regulating gene expression with the use of the same
CA2566519C (en) 2004-05-14 2020-04-21 Rosetta Genomics Ltd. Micrornas and uses thereof
US20070048756A1 (en) 2005-04-18 2007-03-01 Affymetrix, Inc. Methods for whole genome association studies
EP1783645A1 (en) * 2005-11-08 2007-05-09 Actigenics Methods for the identification of microRNA and their applications in research and human health
US8178503B2 (en) 2006-03-03 2012-05-15 International Business Machines Corporation Ribonucleic acid interference molecules and binding sites derived by analyzing intergenic and intronic regions of genomes
JP4841279B2 (ja) 2006-03-23 2011-12-21 一般財団法人 化学物質評価研究機構 被検物質の発がん性予測方法
EP2229186A2 (en) 2007-12-04 2010-09-22 Alnylam Pharmaceuticals Inc. Carbohydrate conjugates as delivery agents for oligonucleotides
BR112014016870A2 (pt) * 2012-01-09 2017-06-27 Huesken Dieter composições orgânicas para tratar doenças relacionadas com beta-catenina
WO2014036301A1 (en) * 2012-08-30 2014-03-06 Isis Pharmaceuticals, Inc. Modulation of copper related diseases by ctr1
PL2992098T3 (pl) 2013-05-01 2019-09-30 Ionis Pharmaceuticals, Inc. Kompozycje i sposoby modulowania ekspresji hbv i ttr
US20160258005A1 (en) * 2013-07-02 2016-09-08 The Trustees Of The University Of Pennsylvania Methods for rapid ribonucleic acid fluorescence in situ hybridization
CN106061981A (zh) 2013-11-06 2016-10-26 索尔斯蒂斯生物有限公司 具有二硫化物基团的多核苷酸构建体
CN107109405A (zh) 2014-06-06 2017-08-29 索尔斯蒂斯生物有限公司 具有生物可逆性和非生物可逆性基团的多核苷酸构建体
EP3164420A4 (en) 2014-06-30 2018-05-23 Tarveda Therapeutics, Inc. Targeted conjugates and particles and formulations thereof
AU2015346042A1 (en) 2014-11-14 2017-04-27 Ionis Pharmaceuticals, Inc. Compounds and methods for the modulation of proteins
US20180002379A1 (en) 2015-01-21 2018-01-04 Sangamo Therapeutics, Inc. Methods and compositions for identification of highly specific nucleases
CN105986015B (zh) * 2015-02-05 2020-10-23 大连晶泰生物技术有限公司 一种基于高通量测序的多样本的一个或多个靶序列的检测方法和试剂盒
EP3286318A2 (en) 2015-04-22 2018-02-28 Mina Therapeutics Limited Sarna compositions and methods of use
EP3386517A4 (en) 2015-12-08 2019-08-07 Solstice Biologics, Ltd. POLYNUCLEOTIDE CONSTRUCTS COMPRISING AN AUXILIARY FRACTION RELATED NON-BIOREVERSIBLE TO AN INTERNETOSIDIC PHOSPHATE OR PHOSPHOROTHIOATE
US11096956B2 (en) 2015-12-14 2021-08-24 Stoke Therapeutics, Inc. Antisense oligomers and uses thereof
WO2017106283A1 (en) * 2015-12-14 2017-06-22 Cold Spring Harbor Laboratory Compositions and methods for treatment of liver diseases
KR101743211B1 (ko) 2016-06-24 2017-06-15 주식회사 녹십자지놈 선천성 기능장애 진단용 조성물 및 이의 용도
CA3107890A1 (en) * 2018-08-21 2020-02-27 Deep Genomics Incorporated Therapeutic splice-switching oligonucleotides
IL308353A (en) * 2021-05-10 2024-01-01 Entrada Therapeutics Inc Compositions and methods for modulating tissue distribution of intracellular therapies
WO2022256283A2 (en) * 2021-06-01 2022-12-08 Korro Bio, Inc. Methods for restoring protein function using adar

Also Published As

Publication number Publication date
PH12020551219A1 (en) 2021-04-19
US11578327B2 (en) 2023-02-14
US20210032629A1 (en) 2021-02-04
BR112020016524A2 (pt) 2021-09-28
CN112041439A (zh) 2020-12-04
KR20200120675A (ko) 2020-10-21
EP3752614A4 (en) 2021-11-10
EP3752614A1 (en) 2020-12-23
CL2020002100A1 (es) 2021-01-29
AU2019222767A1 (en) 2020-08-27
CA3090517A1 (en) 2019-08-22
IL276701A (en) 2020-09-30
WO2019161105A1 (en) 2019-08-22
CO2020010226A2 (es) 2020-12-10
JP2021513851A (ja) 2021-06-03
SG11202007644PA (en) 2020-09-29

Similar Documents

Publication Publication Date Title
NZ733882A (en) Compositions for modulating c9orf72 expression
EP4494706A3 (en) Antisense oligomers for treatment of non-sense mediated rna decay based conditions and diseases
ZA201902226B (en) Aav treatment of huntington's disease
WO2016106406A3 (en) Rna agents for gst-pi gene modulation
PH12020500309A1 (en) Rnai agents and compositions for inhibiting expression of angiopoietin-like 3 (angptl3), and methods of use
MX2010009195A (es) Rnas ultrapequeños como antagonistas del receptor tipo toll-3.
MX2021012126A (es) Composiciones y métodos para inhibir la expresión génica en el sistema nervioso central.
MX358603B (es) Tratamiento de enfermedades relacionadas con un gen supresor de tumor mediante inhibicion del transcrito antisentido natural para el gen.
SG10201808903UA (en) Compositions for modulating c9orf72 expression
CY1121037T1 (el) Αντινοηματικα πολυνουκλεοτιδια για να διεγειρεται παραλειψη εξονιου και μεθοδοι θεραπειας δυστροφιων
EP3800255A3 (en) Rna-guided transcriptional regulation and methods of using the same for the treatment of back pain
WO2008036741A3 (en) Mir-200 regulated genes and pathways as targets for therapeutic intervention
WO2009086156A3 (en) Mir-10 regulated genes and pathways as targets for therapeutic intervention
WO2008073919A3 (en) Mir-20 regulated genes and pathways as targets for therapeutic intervention
WO2008154333A3 (en) Mir-34 regulated genes and pathways as targets for therapeutic intervention
EA201892366A1 (ru) Антисмысловые олигомеры и способы их применения для лечения заболеваний, связанных с геном кислой альфа-глюкозидазы
CL2021001488A1 (es) Transposasa de piggybac mutada
WO2008073923A3 (en) Mirna regulated genes and pathways as targets for therapeutic intervention
MX2023015242A (es) Tratamiento de enfermedades y trastornos relacionados con mtres1.
EA201791986A1 (ru) Олигонуклеотиды, соответствующие экзону 73 гена col7a1, для терапии буллезного эпидермолиза
NZ741841A (en) Antisense oligonucleotides for use in treating alzheimer’s disease
PH12020551219A1 (en) Oligonucleotide therapy for wilson disease
MX2025006351A (es) Tratamiento de trastornos y enfermedades relacionadas con mtres1
MX2020009074A (es) Metodos y composiciones para el tratamiento de condiciones asociadas a la deficiencia del conducto biliar.
MX2025000726A (es) Composiciones de oligonucleótidos y métodos para éstas